Evidence map›Paper›PMID 41278338›Full record

ReviewKidney international reports2025

Antiphospholipid Syndrome and the Kidney.

Maxime Taghavi, Lucas Jacobs, Dario Roccatello, Savino Sciascia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maxime TaghaviNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Lucas JacobsNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Dario RoccatelloCMID-Nephrology and Dialysis Unit, Department of Clinical and Biological Sciences, San Giovanni Bosco Hub Hospital, University of Turin, Turin, Italy, University Center of Excellence on Nephrologic, Rheumatologic, and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member).
Savino SciasciaCMID-Nephrology and Dialysis Unit, Department of Clinical and Biological Sciences, San Giovanni Bosco Hub Hospital, University of Turin, Turin, Italy, University Center of Excellence on Nephrologic, Rheumatologic, and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiphospholipid syndrome (APS) is a rare autoimmune disorder characterized by the persistent positivity of antiphospholipid antibodies (aPLs) along with thrombotic manifestations, obstetrical complications, or nonthrombotic manifestations. The kidney is a major target organ in APS and is associated with poor prognosis. In light of the 2023 American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) classification criteria for antiphospholipid syndrome, this review aims to cover the expanding data on the broad spectrum of renal involvement in aPL carriers and in patients with APS, including microvascular involvement (antiphospholipid syndrome nephropathy) and macrovascular involvement in native kidneys, and in transplant recipients with primary or secondary antiphospholipid syndrome.

Indexed as

antiphospholipid antibody nephropathyantiphospholipid syndromeposttransplant thrombotic microangiopathythrombotic microangiopathy

Identifiers

PMID41278338
PMCPMC12640011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.